COMMUNIQUÉS West-GlobeNewswire

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
09/05/2025
IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged [...]
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
09/05/2025
Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular Diseases ALPHARETTA, Ga., May 09, 2025 (GLOBE NEWSWIRE) -- Clearside [...]
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
09/05/2025
~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse [...]
Anika Reports First Quarter 2025 Financial Results
09/05/2025
First Quarter 2025 Commercial Channel revenue up 18% Integrity ™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for [...]
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
09/05/2025
Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025 [...]
Transactions of Managers and Closely Associated Persons
09/05/2025
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition at the market [...]
École d’allergologie de l’EAACI à Hong Kong 2025 : un modèle pour l’enseignement mondial de l’allergologie
09/05/2025
ZURICH, 09 mai 2025 (GLOBE NEWSWIRE) -- L’Académie européenne d’allergologie et d’immunologie clinique (The European Academy of Allergy & Clinical Immunology, EAACI), en partenariat avec l’Institut d’allergologie de [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
09/05/2025
Bagsværd, Denmark, 9 May 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with [...]
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
09/05/2025
PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the [...]
Spectral Medical Announces First Quarter and Provides Corporate Update
09/05/2025
Tigris Trial Enrollment completed Topline results expected to be released in August 2025 Entered into an up to US$10 million Promissory Note with Vantive to Fund Spectral to PMX commercialization TORONTO, May 09, 2025 ( [...]
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
09/05/2025
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked [...]
Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada
09/05/2025
REYKJAVIK, Iceland, May 09, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its [...]
Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada
09/05/2025
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the BofA Securities Healthcare [...]
BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President
09/05/2025
Jason Keyes is a veteran corporate executive within the biopharmaceutical industry who brings a breadth of leadership experience in the areas of finance, strategic planning and business development SAN DIEGO, May 09, [...]
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
09/05/2025
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Interim analysis from Phase 2 PYNNACLE [...]
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
09/05/2025
DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will [...]
Garuda Therapeutics Announces Name Change to Stratus Therapeutics to Reflect Mission of Pioneering Full Hematopoietic System Renewal
09/05/2025
New corporate identity reflects the continued evolution toward developing the Stratus Prime™ platform to deliver on-demand, Prime HSCs™ and Prime HPCs™ for curative blood and immune system restoration CAMBRIDGE, Mass., [...]
Ocugen Provides Business Update with First Quarter 2025 Financial Results
09/05/2025
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026 Anticipate initiating OCU410ST [...]
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
09/05/2025
Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical [...]

Pages